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Objective: We set out to analyze the incidence and predictive factors of pulmonary
embolism (PE) in hospitalized patients with Covid-19.
Methods: We prospectively collected data from all consecutive patients with
laboratory-confirmed Covid-19 admitted to the Hospital de la Santa Creu i Sant Pau,
a university hospital in Barcelona, between March 9 and April 15, 2020. Patients
with suspected PE, according to standardized guidelines, underwent CT pulmonary
angiography (CTPA).
Results: A total of 1,275 patients with Covid-19 were admitted to hospital. CTPA was
performed on 76 inpatients, and a diagnosis of PE was made in 32 (2.6% [95%CI
1.7–3.5%]). Patients with PE were older, and they exhibited lower PaO2:FiO2 ratios
and higher levels of D-dimer and C-reactive protein (CRP). They more often required
admission to ICU and mechanical ventilation, and they often had longer hospital stays,
although in-hospital mortality was no greater than in patients without PE. High CRP
and D-dimer levels at admission (≥150 mg/L and ≥1,000 ng/ml, respectively) and a
peak D-dimer ≥6,000 ng/ml during hospital stay were independent factors associated
with PE. Prophylactic low molecular weight heparin did not appear to prevent PE.
Increased CRP levels correlated with increased D-dimer levels and both correlated with
a lower PaO2:FiO2.
Conclusions: The 2.6% incidence of PE in Covid-19 hospitalized patients is clearly
high. Higher doses of thromboprophylaxis may be required to prevent PE, particularly
in patients at increased risk, such as those with high levels of CRP and D-dimer at
admission. These findings should be validated in future studies.
Keywords: COVID-19, pulmonary thrombosis, pulmonary embolism (MeSH), thromboprophylaxis, anticoagulant
(MeSH), thromboinflammation
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INTRODUCTION
Since December 2019, the rapid spread of the novel
betacoronavirus, named SARS-CoV-2, has led to a global
pandemic of coronavirus disease 2019 (Covid-19). Several recent
studies have shown that patients with Covid-19 frequently
have coagulation disorders, especially a marked increase in
D-dimer (1–5). These abnormal coagulation parameters have
been associated with worse outcomes (1, 2). It is also suggested
that Covid-19 predisposes patients to a higher risk of thrombotic
disorders, including both venous and arterial thromboembolic
disease (3, 4). Several scientific societies and authors have already
proposed specific guidelines and recommendations on the use of
thromboprophylaxis in patients with Covid-19 (6–11), although
the best thromboprophylaxis regimen (dosing and duration),
taking into account the characteristics of different groups of
patients, has not been established.
To date, a few case series studies (12–19) and some case
reports (17, 20–30) have investigated the incidence and features
of pulmonary thrombosis or embolism (PE) in patients with
Covid-19. All studies included small numbers of cases, and
most of them were conducted in ICU patients (12, 16–19), as
they constitute a particular group with an increased risk of PE
(14). Other studies have been based on patients who underwent
computed tomography pulmonary arteriography (CTPA) but did
not provide clear information on the baseline population (14, 15).
These limitations make it difficult to know the true incidence,
characteristics, and risk factors of PE in patients with Covid-19.
Using a large cohort of consecutive patients with laboratory-
confirmed Covid-19 admitted to a single university hospital, we
sought to analyze the incidence, clinical features, and predictive
factors of PE in patients with Covid-19.
METHODS
Setting
We conducted this study at the Hospital de la Santa Creu i Sant
Pau, a tertiary acute care university hospital in Barcelona, Spain.
The hospital’s Institutional Review Board approved the study.
We collected data prospectively from all consecutive patients
with laboratory-confirmed Covid-19 diagnosed at our hospital
between March 9 and April 15, 2020, and we included those who
were admitted to hospital.
Specific guidance based on the International Society of
Thrombosis and Hemostasis interim guidelines (6) was
developed at our center and distributed on March 18 to all
attending staff. It was recommended to start prophylactic
doses of subcutaneous low molecular weight heparin (LMWH)
(enoxaparin 4,000 IU/24 h, bemiparin 3,500 IU/24 h or
tinzaparin 4,500 IU/24 h) for all patients (including the non-
critically ill) who required hospital admission for Covid-19
in the absence of contraindications. Doses were adjusted to
body weight. On April 3, 2020, the guidance was subsequently
amplified by adding the use of high-dose prophylaxis for patients
at increased thrombotic risk, including those with D-dimer
>3,000 ng/mL (enoxaparin 100 IU/kg/ 24 h, bemiparin 75–80
IU/kg/24 h, or tinzaparin 100 IU/Kg/ 24 h).










Age, years—median (IQR) 66 (13) 60 (17) 0.110
Age ≥ 60 years—no. (%) 24 (75) 22 (50) 0.028
Male gender—no. (%) 20 (62.5) 31 (70.5) 0.466
Diabetes mellitus—no. (%) 6 (18.8) 6 (13.6) 0.546
Hypertension—no. (%) 15 (46.9) 19 (43.2) 0.749
Chronic lung disease—no. (%) 4 (12.5) 12 (27.3) 0.119
Active cancer—no. (%) 5 (15.6) 2 (4.5) 0.124
BMI—median (IQR) 28.1 (5.4) 26.7 (8) 0.527
BMI ≥ 25—no. (%) 22 (75.9) 27 (71.1) 0.660
Obesity—no. (%) 8 (27.6) 13 (32.5) 0.661
Area of admission in the hospital at the time











Days from admission until CTPA
performed—median (IQR)
7 (10.5) 5 (10) 0.398
LMWH administration before CTPA—no. (%) 28 (87.5) 39 (88.6) 1
Days of LMWH administration before
CTPA—median (IQR)
6 (9) 5 (9) 0.922
LMWH doses—no. (%) 0.823
- prophylactic doses








Pneumonia in the CTPA—no. (%) 31 (96.9) 41 (93.2) 0.634
PaO2:FiO2 at the time of performing CTPA 222 (163.5) 250 (181.8) 0.102
Invasive mechanical ventilation at the time of
CTPA—no. (%)
7 (21.9) 6 (13.6) 0.346





Patients needing ICU admission during their
hospital stay—no. (%)
15 (46.9) 10 (22.7) 0.027
Patients requiring invasive mechanical
ventilation during their hospital stay—no. (%)
14 (43.8) 8 (18.2) 0.015





D-dimer at admission ≥ 1,000 ng/mL—no.
(%)
26 (81.3) 23 (52.3) 0.009





Peak D-dimer ≥ 3,000 ng/mL—no. (%) 31 (96.9) 29 (65.9) 0.001
Peak D-dimer ≥ 6,000 ng/mL—no. (%) 29 (90.6) 23 (52.3) <0.001
C-reactive protein at admission,
mg/L—median (IQR)
161.5 (65) 83.5 (126) 0.007
C-reactive protein at admission ≥ 150
mg/L—no. (%)
24 (75) 14 (31.8) <0.001
Peak C-reactive protein, mg/L—median (IQR) 221.5
(169.4)
183 (236.4) 0.059
Hospital stay, days—median (IQR) 15.5 (9.8) 7 (11) 0.010
In-hospital death—no. (%) 3 (9.4) 5 (11.4) 1
BMI, body mass index; CTPA, computed tomography pulmonary arteriography; FiO2,
Fraction of inspired oxygen; IQR, interquartile range; LMWH, low molecular weight
heparin; PaO2 partial pressure of arterial oxygen.
Bold values refer to P-values that are statistically significant (< 0.05); the idea is to make
easer the identification of statistically significant variables in this large table.
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FIGURE 1 | Receiver operating characteristic (ROC) curve for D-dimer and C-reactive protein as predictors of pulmonary embolism in patients with Covid-19. AUC,
area under the ROC curve.
Hospital guidance on when to suspect possible PE and request
a CTPA in Covid-19 patients was also developed and distributed
to all attending staff. Suspicion of having PE included those
patients whose partial pressure of arterial oxygen to fraction
of inspired oxygen (PaO2:FiO2) ratio worsened or failed to
improve, associated with an increasing or persistently high
D-dimer (>3,000 ng/mL) and/or hemodynamic deterioration
or other “classic” symptoms of PE, such as pleuritic chest
pain, hemoptysis, syncope, and/or signs of right ventricular
strain. Patients with suspicion of PE had a CTPA and started
anticoagulant therapy with full-dose LMWH if PEwas diagnosed.
All CTPA scans were performed using a 16-slice multi-
detector CT (Philips Brilliance CT 16C Slice) after intravenous
injection of 60ml iodinated contrast agent (Optiray Ultraject
350 mg/mL Ioversol, Guerbet, France) at a flow rate of 4 mL/s,
triggered on the main pulmonary artery. The CT scan settings
were 120 kVp, slice thickness 2mm, increment 1mm, pitch
0.688, rotation time 0.28 s, and average tube current 300mA.
The location of embolus (main pulmonary, lobar, segmental,
and subsegmental artery) and clot burden (low, moderate, and
high) according to a modified Qanadli Score (31) were evaluated.
Right ventricle overload was also assessed (right ventricle
diameter to left ventricle diameter ratio >1.3). Following the
clinical guidelines developed at our medical center and the
recommendations of the Spanish Agency for Medicinal Products
and Medical Devices (AEMPS), a single dose of intravenous
tocilizumab (600mg for patients ≥75 kg; 400mg for those
<75 kg) was suggested as treatment for hospitalized patients with
Covid-19 and data for cytokine release syndrome.
Variables Assessed
We collected information on patients who underwent
CTPA for suspected PE. Variables included demographic
data, preexisting chronic medical conditions, body mass
index, thrombosis prophylaxis with LMWH and dosing,
diagnosis and characteristics of PE, PaO2:FiO2 ratio,
estimated using methods developed by Brown and
colleagues (32, 33) (PaO2:FiO2 at the time of CTPA and
worst ratio during hospital stay), evolution of D-dimer
and C-reactive protein (at admission and peak level), and
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FIGURE 2 | Correlation between D-dimer and C-reactive protein at admission in patients with Covid-19 and suspected pulmonary embolism (rs = 0.146; p = 0.208).
clinical outcomes, including need for invasive mechanical
ventilation, ICU admission, length of hospital stay, and
in-hospital death.
Statistical Analysis
We summarized continuous variables as medians and
interquartile ranges and categorical variables as percentages
of the total sample for that variable. The incidence of PE
was estimated with a 95% confidence interval (CI). We used
the Wilcoxon rank-sum and chi-square tests (or Fisher’s
exact tests when appropriate) to evaluate group differences
(Covid-19 patients with and without PE in the CTPA)
for continuous and categorical variables, respectively. A
multivariable logistic regression model was used to identify
factors independently associated with a higher risk of
developing PE. Any variable tested in univariate analysis
with a p < 0.25, together with all variables of known
clinical importance, were selected as candidates for the
first multivariate model. We then followed the purposeful
selection of covariates method described by Hosmer et al.
(34) Final parameter estimates are shown as odds ratios (OR)
with their corresponding 95% CIs. Correlations between
quantitative variables were examined using the Spearman rank
correlation test. P < 0.05 were considered to be significant for
all statistical tests. Data were analyzed using IBM R© SPSS R©,
version 26.0.
RESULTS
Of 1,863 consecutive patients diagnosed with laboratory-
confirmed Covid-19 between March 9 and April 15, 2020, at our
center, a total of 1,275 patients (68.4%) were admitted to hospital.
A total of 146 inpatients (12.4%; 95% CI 10.5–14.4%) died during
their hospital stay [101 patients (7.9%) were still hospitalized at
the time of data analysis].
During this period, a CTPA was indicated for suspicion of
PE in 76 inpatients (6% of patients with Covid-19 admitted
to hospital). CTPA confirmed a diagnosis of PE in 32 patients
(42.1% of tests), which represents a cumulative incidence of
2.6% (95 CI 1.7–3.5%) for PE among Covid-19 inpatients. Most
CTPAs were requested for patients admitted to conventional
wards (70%); in fact, a similar percentage of patients with (71.9%)
andwithout PE (68.2%) were hospitalized in the wards at the time
of diagnosis (Table 1).
Table 1 shows the characteristics of Covid-19 inpatients
with and without PE in the CTPA. Patients with PE were
more often ≥60 years old, had lower PaO2:FiO2 ratios, and
had higher levels of D-dimer and C-reactive protein. The D-
dimer levels of these patients were therefore more than five
times higher at hospital admission, and the peak D-dimer
level during hospital stay was more than three times higher
than in patients without PE. Moreover, C-reactive protein at
admission was almost twice as high among PE patients. Covid-
19 inpatients with PE more often required ICU admission
Frontiers in Medicine | www.frontiersin.org 4 August 2020 | Volume 7 | Article 557
Benito et al. Pulmonary Embolism in Covid-19 Patients
and invasive mechanical ventilation than those without PE and
had longer hospital stays, although in-hospital mortality was
not statistically significantly different between the two groups
(9.4% vs. 11.4%). There were also no significant differences
between in-hospital mortality in PE patients and mortality in
all admitted Covid-19 patients (p = 0.604). A high proportion
of patients with and without PE (87.5% and 88.6, respectively)
were receiving LMWH prior to CTPA, mostly at prophylactic
doses, with no statistically significant differences between the
two groups.
We did not investigate deep vein thrombosis (DVT), except in
symptomatic patients. We found DVT in two patients with PE,
one of whom was a patient with gastric cancer.
Candidate variables for the first multivariable model were:
age ≥ 60 years, sex, chronic lung disease, active cancer, BMI,
LMWH administration, D-dimer at admission ≥ 1,000 ng/mL,
C-reactive protein at admission ≥ 150 mg/L, ICU admission,
worst PaO2:FiO2, and peak D-dimer ≥ 6,000. Multivariate
analysis found the following independent factors as associated
with an increased risk of having PE: C-reactive protein at
admission ≥ 150 mg/L (OR 7.9, 95% CI 2.4–26.7), D-dimer at
admission ≥ 1,000 ng/mL (OR 4.5, 95% CI 1.2–17.2, p = 0.026),
and peak D-dimer ≥ 6,000 ng/mL during hospital stay (OR 5.6,
95% CI 1.3–24.5) (Nagelkerke R2 = 0.439).
We analyzed D-dimer and C-reactive protein as predictors of
PE using ROC curves. The peak D-dimer during hospital stay
followed by C-reactive protein at admission had the largest area
under the ROC curve (Figure 1).
We examined a possible linear correlation between levels of
D-dimer and C-reactive protein at admission (Figure 2) and at
their highest levels during hospital stay (Figure 3). A positive
linear correlation was observed in both cases and was statistically
significant for peak D-dimer and peak C-reactive protein values
during hospitalization. We also found statistically significant
negative correlations between peak D-dimer levels and worst
PaO2:FiO2 ratio (Figure 4) and between peak C-reactive protein
levels and worst PaO2:FiO2 ratio (Figure 5) during hospital stay.
In patients with PE, the CTPA showed mainly affection of
the segmental and subsegmental branches of pulmonary arteries,
predominantly with a low thrombus load (Table 2).
DISCUSSION
In this analysis involving a large sample of consecutive patients
hospitalized with Covid-19, we found a high incidence of PE of
2.6% despite the wide use of thromboprophylaxis. Patients with
PE were older and had lower PaO2:FiO2 ratios and markedly
higher levels of D-dimer and C-reactive protein. They more
often required admission to ICU, invasivemechanical ventilation,
and longer hospital stays, although in-hospital mortality was
no greater than in patients without PE. We identified high C-
reactive protein and D-dimer at admission (≥150 mg/L and
FIGURE 3 | Correlation between peak D-dimer and peak C-reactive protein during hospital stay in patients with Covid-19 and suspected pulmonary embolism
(rs = 0.279; p = 0.015).
Frontiers in Medicine | www.frontiersin.org 5 August 2020 | Volume 7 | Article 557
Benito et al. Pulmonary Embolism in Covid-19 Patients
FIGURE 4 | Correlation between peak D-dimer and worst PaO2:FiO2 during hospital stay in patients with COVID-19 and suspected pulmonary embolism
(rs = −0.471; p < 0.001).
≥1,000 ng/ml, respectively) and a peak D-dimer during hospital
stay ≥6,000 ng/ml as independent factors associated with PE.
Prophylactic doses of LMWH did not, however, appear to
prevent PE.
Most of the studies on PE in patients with Covid-19 have
been conducted in ICU patients, who are at greater risk of
venous thromboembolism and have shown incidences ranging
from 17 to 35% (12, 16–19, 35). Interestingly, one of these
studies demonstrated that patients with acute respiratory distress
syndrome (ARDS) due to Covid-19 developed PE significantly
more often than patients with ARDS due to other diseases (11.7%
vs. 2.1%) (18). Another study showed a much higher frequency
of PE in ICU patients with Covid-19 (21%) than during the
same time interval in 2019 (6%), and it was also higher than the
incidence of PE in patients with influenza admitted to the same
ICU in 2019 (8%) (12). It seems clear therefore that the incidence
of PE in patients admitted to ICU with Covid-19 is much higher
than in other critically ill non-Covid-19 patients, including those
with ARDS and other respiratory infections, despite the fact that
these patients are already at an increased risk of PE (10).
The only previous study that has addressed the incidence of
PE in all patients admitted to hospital with Covid-19 found a
percentage of 2.8% (13). Despite the smaller sample size, this
proportion is remarkably similar to that found in the present
study (2.6%). In both studies, the vast majority of patients
(>70%) were admitted to conventional wards. An incidence of
PE close to 3% (which may be underestimated by the number
of patients undergoing CTPA) is certainly high, particularly
when compared with the figure of 1.4% for PE found in a large
prospective study of critically ill patients in the ICU (36).
In most of the studies mentioned above, as was the case
in the present study, patients developed PE even though
most of them were receiving anticoagulant thromboprophylaxis.
These findings raise the need to increase thromboprophylaxis
doses, particularly in higher risk patients (5, 16, 18). The
predictive factors for PE found in the present study can help
identify patients who may benefit from high prophylactic doses.
Patients with C-reactive protein ≥ 150 mg/L and D-dimer
≥ 1,000 could therefore be candidates for increased doses
of thromboprophylaxis; if these patients continue to have a
persistently elevated or increasing D-dimer, however, CTPA
should be considered to diagnose possible PE.
When analyzing all patients with suspicion of PE, we
found that increased C-reactive protein levels (an acute
phase protein whose serum concentrations increase during
inflammatory states and whose expression is driven by IL-
6) (37) correlated with increased D-dimer levels, suggesting
a link between inflammation and procoagulant changes, as
proposed by other authors (5, 38). In fact, increased C-reactive
protein (≥150 mg/mL) at admission was the strongest predictor
of developing PE in multivariable analysis, although peak D-
dimer had greater diagnostic capacity according to the ROC
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FIGURE 5 | Correlation between highest C-reactive protein and worst PaO2:FiO2 during hospital stay in patients with COVID-19 and suspected pulmonary embolism
(rs = −0.473; p < 0.001).
curve. This supports the hypothesis that inflammation associated
with Covid-19 leads to subsequent activation of coagulation
and a higher risk of thrombotic disease (4, 38). Furthermore,
we also demonstrated that both high levels of D-dimer
and C-reactive protein correlated with increased hypoxemia,
evidenced by a decrease in the PaO2:FiO2 ratio. This provides
further important information about the hypercoagulability and
thromboinflammatory response associated with Covid-19 and
their association with acute lung injury.
A relevant debate has arisen recently about whether
thrombosis or pulmonary embolism is the most critical aspect
of pulmonary thromboembolic events in Covid-19 patients (16,
39, 40). These patients are clearly at increased risk for venous
thromboembolic disease (41), and it is therefore not surprising
that they may also develop pulmonary embolisms. Pulmonary
thrombosis in Covid-19 patients found at autopsy (42) and,
remarkably, in all studied patients in one very recent study
(40), however, suggests that pulmonary thrombosis may play a
role in the pathogenesis of more severe cases. Our study does
not permit to differentiate between thrombosis and pulmonary
embolism. Nevertheless, some of our findings would support the
predominance of pulmonary thrombosis. First, the low frequency
of patients with DVT is worthy of note, which is consistent with
other studies (12, 16). Likewise, the predominant involvement in
our study of the segmental and subsegmental pulmonary arteries,
TABLE 2 | Characteristics of pulmonary embolism in the computed tomography
pulmonary angiogram of patients with Covid-19.
Variable Patients with pulmonary
embolism (n = 32)
Location of embolus - no. (%)















Right ventricular overload - no. (%) 5 (15.6)
together with the association between inflammation, coagulation,
and hypoxemia, would also support this hypothesis.
Our study has limitations that are mainly associated with its
observational study design. With such a large number of patients
and the high demand for care during this period, systematic
performance of CTPA in all patients was not possible, which may
have led to underestimating the true incidence of PE. Either way,
any large prospective study including all Covid-19 hospitalized
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patients should probably be based on establishing criteria by
which to evaluate CTPA requests since it does not seem feasible
for all patients to have a CTPA. To enable the standardization of
criteria, our institution developed hospital guidelines on when to
suspect PE and request a CTPA. On the other hand, we compared
the features of patients with and without PE on the basis of
their CTPA results so that our findings cannot be extrapolated
to the entire cohort of inpatients with Covid-19. In order to
obtain results that apply to all hospitalized patients with Covid-
19, we are currently planning a nested case-cohort study that will
include all PE patients diagnosed by CTPA as cases and a random
sample of all Covid-19 inpatients as controls. The CT unit used
in our study was a Phillips Brilliance CT 16-slice scanner, which
is the one reserved at our center for emergencies. During the
Covid-19 pandemic, this CT unit was reserved for the study
of all patients with Covid-19 in order to spare the other CT
units. While better CT image resolution would be obtained with
other more technologically up-to-date units, we think that the
quality of the image, even in subsegmental arteries, is sufficient
for cases of PE. Even so, while the frequency of PE found is
high, it is probably underestimated, as the data from autopsies
of patients with Covid-19 suggest (40, 43). In an autopsy study
of 12 consecutive patients who died from Covid-19, PE was
found in five of them even though no preclinical evidence of PE
had been reported (43). In another study, meticulous autopsies
of 11 deceased patients (10 of whom were selected at random)
observed thrombosis in small to mid-sized pulmonary arteries in
all cases (40).
In conclusion, patients admitted to hospital with Covid-
19 have a high incidence of PE, estimated at 2.6%. Our
study identified predictors of PE able to select patients
at increased risk of developing PE, making them possible
candidates for thromboprophylaxis at higher doses. There is
a correlation between increased levels of C-reactive protein
and D-dimer and increased hypoxemia, which supports the
role of thromboinflammation in acute lung injury observed in
patients with Covid-19. We need more information on the most
appropriate thromboprophylactic doses and duration to prevent
PE in patients with Covid-19.
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